What is the clinical evidence from this study?

Study design: RCT. Population: Healthy participants. Intervention: Citalopram vs. Placebo. Primary outcome: Slope of the loudness dependence of the auditory evoked potential (LDAEP).

November 30, 2005Human Psychopharmacology Clinical and Experimental

Direct evidence that acutely enhancing serotonin with the selective serotonin reuptake inhibitor citalopram modulates the loudness dependence of the auditory evoked potential (LDAEP) marker of central serotonin function

Q: What does this research mean for the field?

Acute enhancement of central serotonin with citalopram decreases the slope of the loudness dependence of the auditory evoked potential (LDAEP) in healthy humans. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

View Full Paper

Ask AI

Bookmark

Key result

Acute citalopram decreases LDAEP slope versus placebo in healthy participants.

Why the study?

Direct evidence in humans linking serotonergic function and the loudness dependence of the auditory evoked potential (LDAEP) has been circumstantial and inconsistent.

Does citalopram modulate the loudness dependence of the auditory evoked potential (LDAEP) in healthy participants?

Population

Healthy participants

Comparison

Citalopram 20 mg acute treatment vs placebo

Design

Double-blind placebo-controlled randomized trial

Authors

PNPradeep J. NathanThe University of Sydney RSRebecca SegraveAustralian Regenerative Medicine Institute KPK. Luan PhanRoyal Prince Alfred Hospital

Discussion

Member takes

Implication

Citalopram acutely modulates LDAEP in healthy adults; confirms its utility as a serotonergic biomarker for pharmacodynamic studies.

Study Design

Type

RCT

Blinding

Double-blind

Structured PICO

Does citalopram modulate the loudness dependence of the auditory evoked potential (LDAEP) in healthy participants?

Population

Healthy participants tested under acute treatment conditions with citalopram and placebo.

Intervention

Citalopram 20 mg acute treatment

Comparator

Placebo

Outcome

Slope of the loudness dependence of the auditory evoked potential (LDAEP)surrogate

Acute administration of citalopram decreases the slope of the LDAEP, validating it as a non-invasive measure of central serotonin function in humans.

Cite This Study

Nathan et al. (2005) conducted an RCT in Healthy participants. Citalopram vs. Placebo was evaluated on Slope of the loudness dependence of the auditory evoked potential (LDAEP). Acute administration of citalopram (20 mg) decreased the slope of the loudness dependence of the auditory evoked potential (LDAEP) compared to placebo in healthy participants.

synapsesocial.com/papers/6aaf3ff26414e77909398e9d https://doi.org/10.1002/hup.740

View Full Paper

Ask AI

Bookmark

Direct evidence that acutely enhancing serotonin with the selective serotonin reuptake inhibitor citalopram modulates the loudness dependence of the auditory evoked potential (LDAEP) marker of central serotonin function

Discussion

Member takes

Implication

Study Design

Structured PICO

Cite This Study

Direct evidence that acutely enhancing serotonin with the selective serotonin reuptake inhibitor citalopram modulates the loudness dependence of the auditory evoked potential (LDAEP) marker of central serotonin function

Discussion

Member takes

Implication

Study Design

Structured PICO

Cite This Study

Also Consider

Also Consider